Company Overview

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros' gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros' lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors, including transcriptionally dependent cancers such as triple negative breast, small cell lung and ovarian cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH Annual Meeting

Nov 1 2017, 9:01 AM EDT

Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference

Oct 30 2017, 8:01 AM EDT

Stock Overview

<table>
<thead>
<tr>
<th>Symbol</th>
<th>SYRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>NASDAQ</td>
</tr>
<tr>
<td>Shares OS</td>
<td>26,260,203</td>
</tr>
<tr>
<td>Market Cap</td>
<td>$398.89M</td>
</tr>
<tr>
<td>Last Price</td>
<td>$15.19</td>
</tr>
<tr>
<td>52-Week Range</td>
<td>$10.22 - $24.375</td>
</tr>
</tbody>
</table>

Investor Relations

Stern Investor Relations, Inc.

Hannah Deresiewicz
hannahd@sternir.com

Management Team

Nancy Simonian, M.D.
President, Chief Executive Officer, and Principal Financial Officer

Eric R. Olson, Ph.D.
Chief Scientific Officer

Gerald E. Quirk
Chief Legal and Administrative Officer

David A. Roth, M.D.
Chief Medical Officer

Syros Pharmaceuticals, Inc.

620 Memorial Drive
Suite 300
Cambridge, MA 02139

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.